Relmada Therapeutics
RLMD
93 hedge funds and large institutions have $66.5M invested in Relmada Therapeutics in 2024 Q1 according to their latest regulatory filings, with 19 funds opening new positions, 21 increasing their positions, 26 reducing their positions, and 9 closing their positions.
111% more first-time investments, than exits
New positions opened: 19 | Existing positions closed: 9
51% more call options, than puts
Call options by funds: $907K | Put options by funds: $602K
17% more capital invested
Capital invested by funds: $56.7M → $66.5M (+$9.79M)
12% more funds holding
Funds holding: 83 → 93 (+10)
1.89% more ownership
Funds ownership: 45.55% → 47.44% (+1.9%)
19% less repeat investments, than reductions
Existing positions increased: 21 | Existing positions reduced: 26
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VPC
Vestal Point Capital
New York
|
+$5.23M |
| 2 |
Franklin Resources
San Mateo,
California
|
+$3.04M |
| 3 |
Jane Street
New York
|
+$786K |
| 4 |
JP Morgan Chase
New York
|
+$757K |
| 5 |
Millennium Management
New York
|
+$687K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DTC
Deep Track Capital
Greenwich,
Connecticut
|
-$3.88M |
| 2 |
Citadel Advisors
Miami,
Florida
|
-$1.47M |
| 3 |
Mirae Asset Global Investments
Seoul,
South Korea
|
-$1.12M |
| 4 |
Point72 Asset Management
Stamford,
Connecticut
|
-$1.03M |
| 5 |
OM
Opaleye Management
Boston,
Massachusetts
|
-$569K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
101
Toronto Dominion Bank
Toronto, Ontario,
Ontario, Canada
| – | -$306 | -74 | Closed |
|
102
Russell Investments Group
London,
United Kingdom
| – | -$219 | -53 | Closed |
|
RLMD Hedge Fund Activity: Q1 2024 in Review
93 of the 6,942 institutional investors tracked by Wall St. Rank reported a position in Relmada Therapeutics (RLMD) for Q1 2024, worth a combined $66.5M — up 17% from $56.7M a quarter earlier.
Buyers outnumbered sellers: 19 funds opened new RLMD positions and 9 closed out — a net gain of 10 holders — while 21 added to existing stakes and 26 trimmed.
The largest buyer was Vestal Point Capital, adding an estimated $5.23M. The largest seller was Deep Track Capital, cutting an estimated $3.88M.
- 93 institutional investors held Relmada Therapeutics (RLMD) as of Q1 2024, up from 83 in Q4 2023.
- Funds reported $66.5M of Relmada Therapeutics stock for Q1 2024, up 17% quarter-over-quarter.
- 19 funds opened new Relmada Therapeutics positions in Q1 2024 and 9 closed out, a net change of +10 holders.
- The largest Relmada Therapeutics buyer in Q1 2024 was Vestal Point Capital, an estimated $5.23M added.
- The largest Relmada Therapeutics seller in Q1 2024 was Deep Track Capital, an estimated $3.88M sold.
Based on aggregated 13F filings for Q1 2024.